Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/123997
Title: | Fabry Nephropathy: An Evidence-based Narrative Review |
Author: | Pino, María Dolores del Andrés, Amado Bernabeu-Sanz, Ana Ávila Juan-Rivera, Joaquín de Fernández, Elvira García Díaz, Juan de Dios Hernández, Domingo Luño, José Martínez Fernández, Isabel Paniagua, José Posada de la Paz, Manuel Rodríguez-Pérez, José Carlos Santamaría, Rafael Torra, Roser Torras Ambròs, Joan Vidau, Pedro Torregrosa Prats, José Vicente |
Keywords: | Malaltia de Fabry Nefrologia Proteïnúria Fabry's disease Nephrology Proteinuria |
Issue Date: | 1-Jan-2018 |
Publisher: | Karger |
Abstract: | Fabry disease (FD) is a rare, X-linked disorder caused by mutations in the GLA gene encoding the enzyme alpha-galactosidase A. Complete or partial deficiency in this enzyme leads to intracellular accumulation of globotriaosylceramide (Gb3) and other glycosphingolipids in many cell types throughout the body, including the kidney. Progressive accumulation of Gb3 in podocytes, endothelial cells, epithelial cells, and tubular cells contribute to the renal symptoms of FD, which manifest as proteinuria and reduced glomerular filtration rate leading to renal insufficiency. A correct diagnosis of FD, although challenging, has considerable implications regarding treatment, management, and counseling. The diagnosis may be confirmed by demonstrating the enzyme deficiency in males and by identifying the specific GLA gene mutation in male and female patients. Treatment with enzyme replacement therapy, as part of the therapeutic strategy to prevent complications of the disease, may be beneficial in stabilizing renal function or slowing its decline, particularly in the early stages of the disease. Emergent treatments for FD include the recently approved chaperone molecule migalastat for patients with amenable mutations. The objective of this report is to provide an updated overview on Fabry nephropathy, with a focus on the most relevant aspects of its epidemiology, diagnosis, pathophysiology, and treatment options. (C) 2018 The Author(s) Published by S. Karger AG, Basel. |
Note: | Reproducció del document publicat a: https://doi.org/10.1159/000488121 |
It is part of: | Kidney & Blood Pressure Research, 2018, Vol. 43, Issue 2, P. 406-421 |
URI: | http://hdl.handle.net/2445/123997 |
Related resource: | https://doi.org/10.1159/000488121 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
del PinoMD.pdf | 608.31 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License